Abstract
On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment. A few respond quickly to treatment and achieve long-term remission. Some fail to achieve remission after induction and the majority respond slowly to treatment. Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT). The use of imatinib along with conventional cytoreductive therapy, prior to allo-SCT appears to be the most promising strategy. The future lies in the molecular evaluation of response to treatment and combination targeted chemotherapy. © 2005 Blackwell Publishing Ltd.
Original language | English |
---|---|
Pages (from-to) | 489-500 |
Number of pages | 11 |
Journal | British Journal of Haematology |
Volume | 130 |
Issue number | 4 |
DOIs | |
Publication status | Published - Aug 2005 |
Keywords
- Childhood
- Philadelphia positive acute lymphoblastic leukaemia